Let Activefol.io Invest in ILMN on Your Behalf.
- Active Investing
- Personalized Strategy
- Low Monthly Fees
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why use an automated portfolio management platform?
Activefol.io is an advanced automated portfolio management platform designed to provides suitable investors with state of the art systematic investment strategies. Its system is designed to screen, monitor and invest in elite stocks like "ILLUMINA, INC. (ILMN)" using Artificial Intelligence to augments your financial potential.
Activefol.io produces short-term trades which makes it ideal for tax-deferred accounts such as IRAs and Roth IRAs. It also works great in taxable accounts. Just be aware that if you elect to auto-trade using Activefol.io in a taxable account, you may be taxed at a higher rate than a long-term investment. Make sure you understand your tax situation before using Activefol.io.
Using Activefol.io is easy. It connects to select Broker / Dealers partners in the United States. All you need to do is to open an account and deposit a minimum of $25,000 in your account to start.
There are clear benefits associated with Activefol.io. The investment system is designed to help you reach your financial goals faster using technology. Activefol.io simplifies stock investing down to a few easy steps. It invests for you, using your personalized strategy, while you attend more important life events.
Using Activefol.io is like having a professional portfolio manager working for you to help you reach your financial goals.
Activefol.io actively invest which is different from passive investing. It is on the lookout working to maximize your potential every minute of every business day of the year. It 'trades on the news' taking advantage of price changes and trends by listening into market changes.
Automated investing really means that a computer program is tasked to monitor and trade stocks based on your carefully crafted strategy.
Automated investing simplifies stock investing by processing and organizing stocks for the purpose of trading.
Once your strategy is set up, all you need to do is start your simulation. Activefol.io executes your strategy by finding and trading stocks that meet specific requirements.
Because you can test and improve your strategy over time, the investment system empowers you to find the appropriate strategy without risking your capital.
Time is your ally when it comes down to systematic investing. Take your time to refine your strategy and learn about the capabilities of our investment system. Patterns will reveal themselves and empower you to develop your real potential.
Activefol.io is one of the first systems to take advantage of Government grade listening technology.
Try Activefol.io today!
You can test your strategy in simulation mode, risk free, Stock Circles today.
Get started now - and see where active automated trading can take you.
Disclaimer: Past performance may not be indicative of future results. Systematic investing, like other investment methods, rely on favorable market conditions to provide positive outcomes.
ILLUMINA, INC. (ILMN) News
Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis
Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
DRAGEN can be run on premise, in the cloud, or in a hybrid mode, and is flexible and compatible for use with multiple cloud storage solutions and analysis pipelines. Edico Genome has built a strong base of NGS customers who have incorporated DRAGEN as a standard part of their sequencing workflow.
“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” said Susan Tousi, Senior Vice President of Product Development at Illumina. “We expect to build on the solid foundation of DRAGEN to deliver a more streamlined and integrated sample to answer experience for our customers.”
The DRAGEN platform complements Illumina’s sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times, to improve their overall efficiency and to allow greater emphasis on interpretation and reporting.
“The scientific community should align around standards to maximize the impact of genomics in health,” said Anthony Philippakis, MD, PhD, Chief Data Officer of the Broad Institute of MIT and Harvard. “We are excited to collaborate with Illumina on approaches and pipelines for the analysis of NGS data. The Genome Analysis Toolkit (GATK) has been adopted by a diverse set of researchers, and we look forward to integrating these methods with Illumina sequencers to improve the overall efficiency of data analysis—enabling the community to more easily share and collaborate.”
“Thanks to Illumina, the ability to generate accurate and affordable sequencing data is rapidly expanding the market and use cases for NGS. As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing,” said Pieter van Rooyen PhD, President and CEO of Edico Genome. “Our team is invigorated at the prospect of joining Illumina to combine our respective strengths to streamline and accelerate secondary analysis for the genomics community.”
“We have had tremendous success at Rady’s for years using Edico’s DRAGEN coupled with Illumina sequencers to accelerate the delivery of genomic insights for critically ill newborns,” said Stephen F. Kingsmore, MD, DSc, President and CEO of Rady Children’s Institute for Genomic Medicine. “Our goal is to ensure that whole-genome sequencing is available to every child who needs it. To do this, we need a rapid workflow that can scale and ultimately be accessible to hospitals around the world.”Get Started today! - Risk Free